Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.

ABSTRACT:

Background

It remains uncertain whether patients with atrial fibrillation (AF) requiring long-term oral anticoagulation (OAC) and with stable coronary artery disease (CAD) should receive antiplatelet therapy (APT) in addition to OAC.

Hypothesis

APT in addition to OAC would be more effective than OAC alone in preventing ischaemic events in such patients.

Methods

In the international REduction of Atherothrombosis for Continued Health (REACH) Registry including 68 236 outpatients with or at risk for atherothrombosis, we identified 2347 patients with stable CAD and AF receiving vitamin K antagonists (VKA). Using propensity score matching, patients treated with VKA (n = 1481) were compared with those receiving VKA + APT at inclusion (n = 866). The primary outcome was major

SUBMITTER: Lemesle G 

PROVIDER: S-EPMC6490437 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature